Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

XRP’s Calm Surface Masks Building Storm

Dieter Jaworski by Dieter Jaworski
November 16, 2025
in Analysis, Blockchain, ETF, Ethereum & Altcoins, Trading & Momentum
0
XRP Stock
0
SHARES
141
VIEWS
Share on FacebookShare on Twitter

The launch of the inaugural US spot ETF for XRP was anticipated to be a landmark event, yet the market response has been unexpectedly subdued. While the price has moved sideways for days, on-chain metrics reveal a different story entirely—one of significant accumulation by major holders. Record-breaking whale transfers suggest that large-scale investors are positioning themselves for a substantial price movement. Is XRP on the verge of a major breakout?

Whale Activity Signals Major Accumulation

Beneath the surface of a stagnant price, a flurry of significant transactions is occurring. On-chain analytics have identified 716 separate transactions, each valued at over $1 million, marking the highest level of such activity in four months. These whale movements, representing a total value of $716 million, point towards substantial portfolio repositioning by heavyweight investors. This divergence between underlying network activity and spot price performance is often a precursor to a significant market move.

Post-ETF Launch Sees “Sell-the-News” Pressure

The market’s reaction to the ETF’s debut has been characterized by a classic “sell-the-news” dynamic. After reaching a high above $2.55 on November 11th, XRP subsequently experienced five consecutive days of declines. This downward trend persisted despite an impressive first-day trading volume of $58 million for the new ETF. The momentum failed to hold, with volume sharply decreasing to $26 million on the second day, underscoring the initial market disappointment. This trend is further compounded by a broader downturn across the cryptocurrency sector, where even established Bitcoin ETFs are facing substantial outflows.

Should investors sell immediately? Or is it worth buying XRP?

Institutional Wave Gathers Momentum

The launch of the Canary Capital ETF is likely just the beginning of a larger institutional push. Several major financial firms, including 21Shares, Bitwise, CoinShares, and Franklin Templeton, are in the process of preparing their own XRP ETF products. This impending wave of institutional offerings has the potential to unlock massive capital flows into the asset in the medium term. In a parallel development, Ripple’s stablecoin, RLUSD, is demonstrating rapid growth, having reached a market capitalization of $1 billion within a single year. This expansion highlights the increasing utility and adoption of the Ripple network beyond mere XRP price speculation.

Consolidation Phase: A Prelude to Movement?

The current market phase presents a classic standoff. Technical indicators are flashing short-term bearish signals, yet the Relative Strength Index (RSI) hints at a potential trend reversal. Key support levels at $2.20 and $2.00 are being closely monitored by traders. Some market participants view this consolidation as a healthy market correction, while others interpret it as a buildup of energy for the next significant upward surge. The critical question is no longer if institutional capital will enter the market through these new ETFs, but when—and whether that influx will finally provide the catalyst for XRP to break out of its tight trading range.

Ad

XRP Stock: Buy or Sell?! New XRP Analysis from February 8 delivers the answer:

The latest XRP figures speak for themselves: Urgent action needed for XRP investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

XRP: Buy or sell? Read more here...

Tags: XRP
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Bitcoin Stock

Is Bitcoin Nearing a Turning Point?

Marin Software Stock

Marin Software Equity Wiped Out in Bankruptcy Liquidation

AMD Stock

AMD's AI Surge Fuels Record-Breaking Quarter

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com